Lung cancer is a leading cause of cancer-related deaths in China, commanding increasing attention. The prevailing therapeutic strategies includes chemotherapy, targeted therapies and immunotherapy. However, the emergence of drug resistance and disease progression are inevitable challenges, underscoring an imperative for the development of more efficacious strategies to enhance patient prognoses. Antibody-drug conjugates (ADCs) , a novel paradigm in oncology, have shown promising therapeutic potential in a variety of solid tumors. This article focus on the cutting-edge research and advancements of ADCs in lung cancer therapy.